Leo's failures the past 5 years...
Over hyping 2014/15, then telegraphing his intentions to up-list, fueling the shorts while never qualifying with improper BOD's in place.
Zero strategy on ABSSSI after proclaiming himself a genius after the Merck/Cubist deal. Still today, there's no direction on ABSSSI.
Waiting a year too late to add more experience. Dr B has been great, but Leo needed to walk away from control back in 2015...
Too many press releases over the years referencing billions, tremendous, partners and so on...
Inability to find major investors or lenders to help move science along... Why couldn't ABSSSI draw interest?
Not fighting Aruda for the gifted shares... Still haunts the company today as K has been a bust.
Too much time worrying about Mako instead of focusing on the task at hand... The Rosen counter lawsuit was never going to win, a waste of shareholder funds.
420K salaries for 3 employees is way too high for a company that's bleeding cash. That's 15 percent of the yearly budget.
P interim? Seems odd to cancel this "with no explanation" after twice projecting it to occur. Which only fuels questions about trial progress.
Launching a 10 patient trail (K) and after 8 months needing an additional site giving no explanation? What's going on here?
BOD additions? Most promising biotechs add meaningful board additions. Who are the current BOD's and what roles do they serve? Are they looking out for the best interests of the shers? Do they have meetings and approve the salary structure?
The stock is where it's at due to poor CEO leadership by not being able to promote the business and find any major investment. Aspire is not shareholder friendly.
The real reasons for this stock trading in-the-toilet is clear-as-day.
